General characteristics of the study population
| . | Control patients (n = 334) . | Patients with provoked PE (n = 259) . | Patients with unprovoked PE (n = 95) . |
|---|---|---|---|
| Sex (female), %* | 211 (63) | 137 (53) | 49 (55) |
| Age, y (mean ± SD)*† | 48 ± 17 | 52 ± 18 | 55 ± 17 |
| History of arterial cardiovascular events, n (%)† | 40 (12) | 38 (15) | 17 (18) |
| Active malignancy, n (%)*† | 46 (14) | 103 (40) | — |
| Diabetes, n (%)† | 17 (5.1) | 12 (4.6) | 6 (6.3) |
| Active smoker, n (%)† | 110 (33) | 78 (30) | 30 (32) |
| Use of blood pressure–lowering medication, n (%)‡ | 107 (32) | 91 (35) | 34 (36) |
| Use of antiplatelet therapy, n (%)‡ | 50 (15) | 37 (14) | 17 (18) |
| Use of lipid-lowering medication, n (%)‡ | 57 (17) | 42 (16) | 18 (19) |
| No. of patient-years in follow-up | 1284 | 817 | 349 |
| . | Control patients (n = 334) . | Patients with provoked PE (n = 259) . | Patients with unprovoked PE (n = 95) . |
|---|---|---|---|
| Sex (female), %* | 211 (63) | 137 (53) | 49 (55) |
| Age, y (mean ± SD)*† | 48 ± 17 | 52 ± 18 | 55 ± 17 |
| History of arterial cardiovascular events, n (%)† | 40 (12) | 38 (15) | 17 (18) |
| Active malignancy, n (%)*† | 46 (14) | 103 (40) | — |
| Diabetes, n (%)† | 17 (5.1) | 12 (4.6) | 6 (6.3) |
| Active smoker, n (%)† | 110 (33) | 78 (30) | 30 (32) |
| Use of blood pressure–lowering medication, n (%)‡ | 107 (32) | 91 (35) | 34 (36) |
| Use of antiplatelet therapy, n (%)‡ | 50 (15) | 37 (14) | 17 (18) |
| Use of lipid-lowering medication, n (%)‡ | 57 (17) | 42 (16) | 18 (19) |
| No. of patient-years in follow-up | 1284 | 817 | 349 |